作者
Frank I Scott, Ronac Mamtani, Colleen M Brensinger, Kevin Haynes, Zelma C Chiesa-Fuxench, Jie Zhang, Lang Chen, Fenglong Xie, Huifeng Yun, Mark T Osterman, Timothy Beukelman, David J Margolis, Jeffrey R Curtis, James D Lewis
发表日期
2016/2/1
期刊
JAMA dermatology
卷号
152
期号
2
页码范围
164-172
出版商
American Medical Association
简介
Importance
Immune dysfunction underlies the pathogenesis of rheumatoid arthritis (RA) and inflammatory bowel disease (IBD). Immunosuppressive therapy is the standard of care for these diseases. Both immune dysfunction and therapy-related immunosuppression can inhibit cancer-related immune surveillance in this population. Drug-induced immunosuppression is a risk factor for nonmelanoma skin cancer (NMSC), particularly squamous cell tumors. For patients with a history of NMSC, data are limited on the effect of these drugs on the risk of additional NMSCs.
Objective
To determine the relative hazard of a second NMSC in patients with RA or IBD who use methotrexate, anti–tumor necrosis factor (anti-TNF) therapy, or thiopurines after an initial NMSC.
Design, Setting, and Participants
In this retrospective cohort study, we studied 9460 individuals with RA or IBD enrolled in Medicare from January 1, 2006, through …
学术搜索中的文章
FI Scott, R Mamtani, CM Brensinger, K Haynes… - JAMA dermatology, 2016